PATENT CLAIM ANALYSIS

Application Number: 16329154
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "444000"]

Abstract:
The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Claim (Index 17):
The method according to  claim 16 , wherein the senescence-related disease is at least one selected from the group consisting of heart failure, arteriosclerosis, arteriosclerotic cerebrovascular or cardiovascular disease, hypertension, cerebral infarction, cerebral hemorrhage, dyslipidemia, pulmonary fibrosis, emphysema, skeletal muscle atrophy (sarcopenia), osteoarthritis, dementia, frailty, cancer, chronic kidney disease, cataract, glaucoma, age-related macular degeneration, presbyopia, age-related alopecia, age-related hearing loss, pain associated with aging such as lumbar pain and joint pain, asteatotic eczema, cutaneous pruritus, fatty liver, nonalcoholic steatohepatitis (NASH), liver cirrhosis, osteoporosis, osteoarthropathy, Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and Rothmund-Thomson syndrome.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15565317', '15455684', '15956613', '15827539', '16007880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7843520260289407
- 35 USC 102 Novelty (BERT): 0.4961529117439168
- Combined Prediction Score: 0.7555321146004383
- Mean Citation Score: 225.980686
- Max Citation Score: 238.07213
- Similarity Product: 172.28086340832112

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test